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Abstract
Rationale:Methicillin-resistant Staphylococcus aureus (MRSA)
prevalence continues to increase in patients with cystic fibrosis (CF)
in the United States, reaching 26.5% in 2012. Approximately 30%
of strains are SCCmec (staphylococcal cassette chromosome mec)
IV type, frequently USA300, which in the general population have
different genotypic and phenotypic features than SCCmec II type.
Objectives:We hypothesized that risk factors for acquisition and
outcomes in patients with CF differed for “health care–associated”
(SCCmec II) versus “community-associated” (SCCmec IV)MRSAstrains.
Methods: To determine the role of SCCmec type and Panton–
Valentine leukocidin (PVL), MRSA isolates from patients not more
than 18 years old at seven CF centers were typed and the association
of potential risk factors and subsequent clinical course was assessed,
using data provided by the CF Patient Registry.
Measurements and Main Results: Participants with chronic
MRSA (295) had typeable isolates and clinical data; 205 (69.5%) had
SCCmec II PVL(–), 39 (13.2%) had SCCmec IV PVL(–), and 51 (17.3%)
hadSCCmec IVPVL(1) strains. SCCmec IV, comparedwith SCCmec II,
increased during the study period, 1996–2010 (P = 0.03). SCCmec II
was associated with Pseudomonas aeruginosa–positive cultures and
three or more clinic visits in the 6 months preceding the first positive
MRSA culture (adjusted odds ratio, 2.05; 95% confidence interval,
1.13–3.74; P = 0.019). Lung function and anthropometrics remained
unchanged in the 6months after initialMRSAdetection comparedwith
the 6months prior. Although CF care increased for participants in both
groups in the 6 months after MRSA detection, inhaled antibiotics
were prescribed more frequently in those with SCCmec II strains and
increased hospitalizations occurred in those with SCCmec IV PVL(–)
strains compared with those with PVL(1) strains (adjusted difference,
34.10%; 95% confidence interval, 7.58–60.61; P = 0.012). Participants in
both groups had an increase in CF care in the 2 years after MRSA
detection compared with the 2 years prior.
Conclusions: Increased exposure to CF clinics and P. aeruginosa
may constitute risk factors for acquisition of SCCmec II MRSA
strains. Clinical interventions increased 6 months and 2 years after
initial MRSA detection regardless of SCCmec type.
Keywords: SCCmec type; Panton–Valentine leukocidin; risk
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(Received in original form December 28, 2014; accepted in final form February 17, 2015 )
*Present address: Division of Pediatric Pulmonary Medicine, Children’s Hospital of Richmond at Virginia Commonwealth University, Richmond, Virginia.
†
STAR-CF Study Team: Participating investigators who collected data at their study site and provided and cared for study patients are listed in alphabetical
order of the study site. Children’s Hospital of Pittsburgh, Pittsburgh, Pennsylvania (Daniel J. Weiner, M.D.); Columbia University, New York (Lynne Quittell,
M.D.); Emory University, Atlanta, Georgia (Michael Schechter, M.D., M.P.H.); Riley Hospital for Children, Indianapolis, Indiana (Michelle Howenstine, M.D.);
St. Louis Children’s Hospital, St. Louis, Missouri (Thomas Ferkol, M.D.); University of Alabama at Birmingham, Birmingham, Alabama (Wynton Hoover, M.D.);
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (Marianne Muhlebach, M.D.)
Supported by Cystic Fibrosis Foundation Therapeutics in the form of a grant (MUHLEB08A0).
Correspondence and requests for reprints should be addressed to Marianne S. Muhlebach, M.D., 450 MacNider, 333 S. Columbia Street, CB #7217, University
of North Carolina at Chapel Hill, Pediatric Pulmonology, Chapel Hill, NC 27599-7217. E-mail: marianne_muhlebach@med.unc.edu
Ann Am Thorac Soc Vol 12, No 6, pp 864–871, Jun 2015
Copyright © 2015 by the American Thoracic Society
DOI: 10.1513/AnnalsATS.201412-596OC
Internet address: www.atsjournals.org
864 AnnalsATS Volume 12 Number 6| June 2015
 
Lung infections caused by methicillin-
resistant Staphylococcus aureus (MRSA)
have markedly increased in patients with
cystic fibrosis (CF) (1), reaching 26.5%
prevalence in the United States in 2012
(2). Chronic MRSA is associated with
a more rapid decline in lung function
and increased mortality (3, 4). These
epidemiologic studies did not account for
the genetic lineage of MRSA, which is
warranted in patients with CF based
on differences in risk factors, clinical
presentations, and outcomes in the
general population (5).
Methicillin resistance is conferred
by the mecA gene located within the
staphylococcal cassette chromosome
(SCC) (6). Several SCCmec types have
been described (7), of which SCCmec II
is more commonly found in so-called
hospital-associated (HA)-MRSA
infections, whereas SCCmec IV is more
commonly found in the community-
associated (CA)-MRSA infections in the
United States (8). Differences in the
clinical presentations include the
invasive/systemic disease typically seen
in patients with comorbidities acquiring
HA-MRSA (9–12) whereas CA-MRSA
typically causes skin and soft tissue
infections in previously healthy
individuals (13). SCCmec IV strains may
also carry the putative virulence factor
Panton–Valentine leukocidin (PVL),
which is commonly detected in USA300—
the epidemic SCCmec IV strain in the
United States (14). In some reports PVL
status has been associated with more
severe disease (15, 16), including in
children with CF (17); however, the role
of PVL remains debated (18).
Another key distinction between the
SCCmec types is differential antibiotic
resistance: SCCmec II encodes resistance
to more antibiotic classes whereas the
smaller SCCmec IV element encodes fewer
antibiotic resistance genes. Thus, SCCmec
IV strains are more likely to be susceptible
to clindamycin, fluoroquinolone agents,
and trimethoprim–sulfamethoxazole
(TMP–SMX). We previously reported
similar differences in the antibiotic
susceptibilities of MRSA isolates from
children with CF; SCCmec II isolates
had higher frequencies of resistance to
clindamycin and ciprofloxacin compared
with SCCmec IV isolates (19).
Among U.S. patients with CF infected
with MRSA, about two-thirds harbor
SCCmec II strains (20–22). Several studies
show that patients remain infected with
the same strain for many years; thus,
typing at one time point is indicative of
past and future MRSA type (22, 23). In
a single-center study, we reported that
children and adults with CF infected
with SCCmec II strains were older, had
longer duration of MRSA infection, and
were more frequently coinfected with
Pseudomonas aeruginosa when compared
with patients infected with SCCmec IV
strains expressing PVL (24). In addition,
in a multicenter study, we showed that
pediatric patients with CF chronically
infected with SCCmec II strains had
a higher rate of treatment with oral
antibiotics for protocol-defined pulmonary
exacerbations than those with SCCmec IV
strains (25). Thus, SCCmec type appears
to be associated with different clinical
outcomes in patients with CF.
In the current multicenter study, we
evaluate risk factors for initial infection with
the two MRSA SCCmec types (II vs. IV)
among children with CF who remain
persistently culture positive. We also
evaluate risk factors for and outcomes
associated with PVL among those children
infected with SCCmec IV PVL(1) versus
PVL(–) strains. We hypothesize that
children with CF persistently infected with
SCCmec II MRSA strains had more contact
with the health care environment, before
acquisition and/or more severe CF disease
than those infected with SCCmec IV MRSA
strains. In turn, we examine clinical
outcomes after initial infection to evaluate
whether SCCmec type and PVL status are
related to subsequent changes in disease
course.
Methods
Study Design, Sites, and Participants
We performed an observational, multicenter
study to assess clinical characteristics
and potential risk factors associated with
acquisition of various MRSA strains based
on SCCmec typing and the presence of the
PVL gene. Seven geographically diverse,
Cystic Fibrosis Foundation (CFF)–
accredited pediatric centers, each treating
more than 200 children and adolescents
and having at least 20% MRSA prevalence,
participated in this study. Eligible
participants with CF were not more than
18 years of age and had two or more
cultures positive for MRSA within at least
one of the 2 years preceding enrollment.
Participants in whom no MRSA-positive
culture could be obtained at enrollment/
consent into this study and/or at two
subsequent CF clinic visits were excluded
from analyses (Figure 1). Patients who had
undergone lung or liver transplantation
were not eligible to participate. Each
center’s institutional review board
approved the study. Written consent was
obtained from parents, and assent was
obtained from children old enough to
read.
Typing of MRSA Isolates
Participant respiratory cultures
(deep pharyngeal swab, sputum, or
bronchoalveolar lavage) were processed at
each site’s clinical microbiology laboratory
according to CFF guidelines (26). Three
colonies of MRSA from the same culture
were sent to the core laboratory at the
University of North Carolina (Chapel
Hill, NC), where the SCCmec type
and presence of the PVL gene were
determined by PCR methods as previously
described (22, 27).
Data Collection
Data from the U.S. CFF Patient Registry
were obtained from January 1996
through December 2012 and included
demographic characteristics, cystic fibrosis
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transmembrane conductance regulator
(CFTR) mutations, microbiology results,
number of clinic visits, chronic CF
medications, treatment with intravenous
(IV) antibiotics, spirometry results, and
growth parameters. Spirometry was
ascertained in children at least 6 years old
and expressed as FEV1 % predicted (28, 29).
Weight for length in children less than
2 years of age, or body mass index (BMI)
percentiles in children 2 years of age or
older, were calculated on the basis of
Centers for Disease Control and Prevention
reference values (30, 31). Hospital
admissions (for any reason) and treatment
with IV antibiotics in the home have
been available in the CFF Patient Registry
since 2003.
Statistical Analyses
Year of MRSA acquisition during our
study was stratified into three periods
based on changes in MRSA prevalence
and the emergence of USA300 (8, 14).
Demographic and clinical characteristics
were described using summary
statistics and compared among
participants with different SCCmec
types and PVL status, using two-sided
t tests for continuous variables or
Fisher’s exact test for categorical
variables. Values for FEV1% predicted
and BMI (ages >2 yr) or weight
for length (,2 yr of age) were
averaged over 2 years. Microbiologic
factors included detection of “any”
methicillin-susceptible S. aureus
(MSSA) or P. aeruginosa, and chronic
infection with MSSA or P. aeruginosa
defined as more than 50% of cultures
positive in the year before MRSA
detection (32).
To assess short-term (i.e., within
6 mo) risk factors for acquisition and
clinical outcomes of various MRSA types,
chronic CF medications, clinic visits,
hospitalizations, and treatment with
intravenous antibiotics were compared
among participants with different
SCCmec types and PVL status. Paired
summaries of the change from 6 months
before and the 6 months after MRSA
acquisition, and 95% confidence intervals
(CIs) were reported. To test whether
changes differed by SCCmec type or
PVL status, an analysis of covariance
was performed, adjusted for sex, age,
and year of MRSA acquisition, study site,
and presence of any P. aeruginosa. To test
our primary hypothesis, a multivariate
logistic regression model was fit to
estimate the odds of acquisition of
SCCmec MRSA type by health care
exposures, that is, number of CF clinic
380 participants enrolled ≥ 2 positive MRSA cultures





and negative at two
subsequent cultures*
4 excluded: MRSA non-
typeable isolates
15 excluded: insufficient
data available in CF
















Figure 1. Flow diagram of participants included in final analyses. *Participants were excluded
from further analysis as this study focused on those with persistently positive methicillin-resistant
Staphylococcus aureus (MRSA) cultures. Participants who did not provide a positive MRSA culture
did not differ from eligible participants for Pseudomonas aeruginosa or lung function, but had fewer
MRSA-positive cultures overall (42).
Table 1. Year of initial positive isolate by methicillin-resistant Staphylococcus aureus SCCmec type and Panton–Valentine
leukocidin status









1996–2002 45 (22.0%) 9 (10.0%) 0.002* 7 (18.0%) 2 (3.9%) 0.033*
2003–2006 97 (47.3%) 35 (38.9%) 17 (43.6%) 18 (35.3%)
2007–2010 63 (30.7%) 46 (51.1%) 15 (38.5%) 31 (60.8%)
Definition of abbreviation: PVL = Panton–Valentine leukocidin; SCCmec = staphylococcal cassette chromosome mec.
Boldface indicates significance at the 0.05 level.
Proportion of cultures and their distribution over the years of study are shown.
*P value for Fisher’s test of distributional differences between SCCmec types and PVL status.
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visits or hospitalizations, adjusted for the
aforementioned confounding variables.
Similarly, to assess longer term
outcomes (i.e., within 2 yr) associated
with SCCmec type and PVL status, the
aforementioned variables were summarized
as described above for participants in the 2
years before and after MRSA acquisition. In
addition, changes in FEV1% predicted and
BMI/weight-for-length percentiles were
assessed. All analyses were performed with
SAS version 9.2 (SAS, Cary, NC) and two-
sided P values are reported.
Results
Study Population and MRSA Type
From October 2008 to April 2010, 380
potentially eligible participants with
a history of MRSA infection were enrolled.
After exclusion of 85 participants as detailed
in Figure 1, 295 participants were included
in this study. Distribution of SCCmec
types and PVL status is shown in Table 1.
The proportion of participants with
SCCmec IV strains was lowest among those
with initial MRSA detection from 1996 to
2002 and increased over time; 51% of all
SCCmec IV strains were detected from 2007
to 2010 (Table 1). Similarly, the presence of
the PVL gene among SCCmec IV strains
increased over time; from 1996 to 2002,
3.9% of strains were PVL(1) whereas
from 2007 to 2010, 60.8% of strains were
PVL(1).
Characteristics Associated with
Acquisition of Various MRSA Types
The mean age for all participants at the
time of their first MRSA-positive culture
was 7.0 (SD 4.2) years and was similar
among participants with different SCCmec
types. The distributions of age, sex, and
CFTR genotypes were also similar among
those who acquired different SCCmec types;
56.1% of those with SCCmec II versus
47.8% of those with SCCmec IV MRSA
strains were F508 del homozygote.
In the 2 years before the first
MRSA-positive culture, anthropometric
percentiles were similar for those who
acquired SCCmec II versus SCCmec IV
(Table 2). Lung function, available for
110 participants with SCCmec II and for
44 with SCCmec IV isolates, was also
similar in the two groups.
In the 6 months before first MRSA-
positive culture, more participants who
acquired SCCmec II strains had at least
one P. aeruginosa–positive culture
(Table 2). However, the proportion of
participants with chronic P. aeruginosa did
not differ by SCCmec type. Differences in
P. aeruginosa–positive cultures were not
secondary to more frequent assessment
as the number of cultures was similar
for participants with SCCmec II versus
SCCmec IV isolates (mean [SD], 3.1[1.7]
vs. 3.0 [1.9]).
Among participants with SCCmec IV,
none of the above-described characteristics
were associated with the PVL gene (data
not shown).
In the 6 months before first
MRSA-positive cultures, the use of chronic
CF medications and days of intravenous
antibiotic treatment of pulmonary
exacerbations were similar in the two
groups (Table 2). However, a greater
proportion of participants who acquired
SCCmec II strains had three or more CF
clinic visits compared with those who
acquired SCCmec IV. This observation
persisted when adjusted for the covariates
Table 2. Demographic and clinical characteristics associated with various methicillin-






Age group, yr: n (%)
,3 42 (20.5%) 16 (17.8%) 0.86*
3 to ,6 42 (20.5%) 21 (23.3%)
6 to ,10 87 (42.4%) 36 (40.0%)
>10 to 18 34 (16.6%) 17 (18.9%)
Sex, n (%)
Female 106 (51.7%) 39 (43.3%) 0.21
Health status 24 mo before MRSA:
n, mean (SD)
FEV1% predicted
† 110, 89.1 (16.8) 44, 84.6 (20.4) 0.16
BMI or weight/height percentile‡ 196, 44.4 (27.0) 80, 44.9 (27.2) 0.90
Microbiology before MRSA acquisition,
n (%)
MSSA any (6 mo prior) 58 (28.3%) 22 (24.4%) 0.57
MSSA chronicx (1 yr prior) 35 (17.1%) 16 (17.8%) 0.87
P. aeruginosa any (6 mo prior) 96 (46.8%) 27 (30.0%) 0.007
P. aeruginosa chronicx (1 yr prior) 61 (29.8%) 18 (20.0%) 0.088
CF medications 6 mo before MRSA
acquisition
Chronic use of inhaled antibiotics,
n (%)
72 (35.1%) 25 (27.8%) 0.23
Chronic use of DNase, n (%) 67 (32.7%) 30 (33.3%) 0.99
Chronic use of macrolides, n (%) 34 (16.6%) 12 (13.3%) 0.60
Days of IV antibiotics per IV
coursejj¶**: n, mean (SD)
47, 13.4 (8.1) 21, 10.2 (6.7) 0.12
Health care exposure 6 mo
before MRSA acquisition
CF clinic visits, n (%)
0 20 (9.8%) 18 (20.0%) 0.007
1 or 2 108 (52.7%) 52 (57.8%)
>3 77 (37.5%) 20 (22.2%)
>1 hospitalization,jj n (%) 44 (27.5%) 20 (24.7%) 0.76
Hospital days per admissionjj**:
mean (SD)
9.0 (6.8) 8.0 (5.5) 0.57
Definition of abbreviations: BMI = body mass index; CF = cystic fibrosis; IV = intravenous; MRSA =
methicillin-resistant Staphylococcus aureus; MSSA =methicillin-susceptible Staphylococcus aureus;
P. aeruginosa = Pseudomonas aeruginosa; SCCmec = staphylococcal cassette chromosome mec.
Boldface indicates significance at the 0.05 level.
*P value for Fisher’s test of distributional differences between SCCmec types.
†For participants 6 years of age or older.
‡Weight/height percentiles in children less than 2 years of age and BMI percentiles in those 2 years
of age and older.
xChronic defined as greater than 50% of cultures in 12 months positive for the pathogen.
jjEvaluable in n = 160 SCCmec II and n = 81 SCCmec IV with data after 2003.
¶Combined inpatient and outpatient intravenous therapy.
**Mean and SD reported among those with event/hospitalization (excluding 0s).
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(adjusted odds ratio, 2.05; 95% CI,
1.13–3.74; P = 0.019). The frequency of
hospitalization and days of hospitalization
were not associated with SCCmec type
when adjusted for covariates (adjusted
odds ratio, 0.99; 95% CI, 0.52–1.89;
P = 0.97).
Changes in Clinical Parameters from
6 Months before to after Detection of
Various MRSA Types
The association of SCCmec II versus
SCCmec IV MRSA with changes in
clinical care and outcomes from
6 months before to 6 months after initial
MRSA detection is shown in Table 3.
Differences between the two groups,
adjusted for covariates, are also shown.
The use of chronic CF medications
increased within both groups, with the
exception that the use of inhaled
antibiotics remained unchanged in those
with SCCmec IV strains but increased
significantly in those with SCCmec II
strains. The greatest percent increase
occurred for use of DNase for both
groups. The number of CF clinic visits
increased regardless of SCCmec type.
P. aeruginosa–positive cultures,
hospitalizations, and duration of
hospitalization were similar before and
after MRSA detection and were similar
by SCCmec type. There were no
significant changes in lung function or
anthropometric parameters.
Among participants with SCCmec IV,
those with PVL(–) strains had a significant
increase in the use of DNase (15.38%; 95%
CI, 1.4, 29.37) and the chronic macrolide
agents azithromycin and clarithromycin
(12.82%; 95% CI, 1.84, 23.8). In contrast,
those with PVL(1) strains had
a significant increase in the use of inhaled
antibiotics (7.84%; 95% CI, 0.21, 15.48).
However, none of these differences were
significant between the groups when
adjusted for covariates. Participants
having at least one hospitalization
significantly increased among those with
PVL(–) (17.95%; 95% CI, –0.07, 35.97)
compared with those with PVL(1) strains
(–9.80%; 95% CI, –24.96, 5.35) and this
difference remained significant after
adjusting for covariates (adjusted
difference, 34.10%; 95% CI, 7.58, 60.61;
P = 0.012).
Changes in Clinical Parameters from
2 Years before to after Detection of
Various MRSA Types
Lung function, but not anthropometric
measures, significantly declined in the
2 years after MRSA detection compared
with the 2 years prior, regardless of SCCmec
status (Table 4). Similarly, CF medication
use and CF clinic visits also significantly
increased in all participants compared with
2 years prior. In contrast, hospitalizations
and IV antibiotic days per IV course
significantly increased only for those with
SCCmec II strains, and P. aeruginosa–
positive cultures increased significantly in
those with SCCmec IV strains. Whereas the
number of cultures increased in each group,
similar numbers of cultures were obtained
before and after detection of MRSA; the
mean (SD) cultures/participant/24 months
was 5.4 (3.3) versus 5.3 (3.9) for those with
SCCmec II versus SCCmec IV strains,
respectively (P = 0.98) before MRSA
detection and 8.6 (3.9) versus 9.1 (3.8) for
those with SCCmec II versus SCCmec IV
strains, respectively (P = 0.30) after MRSA
acquisition. None of the changes that
occurred within SCCmec type were
Table 3. Changes in clinical parameters 6 months before compared with after detection of various methicillin-resistant
Staphylococcus aureus types
Change within SCCmec II
(n = 205)
Change within SCCmec IV
(n = 90)
Adjusted* Difference between SCCmec Type
(SCCmec II–SCCmec IV)
n Mean 95% CI n Mean 95% CI Mean Difference 95% CI P Value
Health status
FEV1% predicted 102 20.1 –2.23, 2.04 34 21.45 –5.15, 2.25 2.49 –2.26, 7.25 0.30
BMI or weight/stature
percentile
180 20.56 –2.74, 1.62 68 2.87 –0.68, 6.41 22.48 –6.78, 1.82 0.257
CF medications 205 90
Chronic inhaled
antibiotics
17.56% 9.75, 25.37 4.44% –1.76, 10.65 12.87% –0.44, 26.19 0.058
Chronic DNase 18.05% 11.35, 24.75 11.11% 3.14, 19.08 7.50% –4.62, 19.62 0.22
Chronic azithromycin 8.29% 4.25, 12.34 7.78% 2.14, 13.42 0.00% –7.43, 7.31 0.98
Days of IV antibiotics
per IV course†‡
160 2.62 0.18, 5.06 81 2.06 –0.51, 4.63 1.48 –2.59, 5.54 0.48
Microbiology
Any P. aeruginosa 205 21.46% –7, 4.07 90 21.11% –8.47, 6.25 24.75% –14.09, 4.59 0.32
Health care exposure
CF clinic visits 205 0.84 0.52, 1.16 90 1.00 0.44, 1.56 20.030 –0.65, 0.60 0.94
>1 hospitalization 205 6.83% –0.19, 13.85 90 2.22% –9.52, 13.96 4.16% –9.78, 18.11 0.56
Days inpatient per
hospitalization
160 0.72 –0.35, 1.78 81 1.02 –0.87, 2.92 20.39 –2.53, 1.75 0.72
Definition of abbreviations: BMI = body mass index; CF = cystic fibrosis; CI = confidence interval; IV = intravenous; MRSA =methicillin-resistant
Staphylococcus aureus; P. aeruginosa = Pseudomonas aeruginosa; SCCmec = staphylococcal cassette chromosome mec.
Changes are shown for characteristics before compared with after MRSA by SCCmec types and adjusted changes. Boldface indicates significance at
the two-sided 0.05 level.
*Comparisons by SCCmec type are adjusted for site, sex, age, year of MRSA onset, and P. aeruginosa during the 6 months after MRSA acquisition.
†Evaluable in n = 160 SCCmec II and n = 81 SCCmec IV with data after 2003.
‡Combined inpatient and outpatient intravenous therapy.
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significantly different between the two
SCCmec types, adjusted for covariates.
In participants with SCCmec IV,
changes in clinical parameters in the
2 years before versus 2 years after MRSA
acquisition were similar in those with and
without the PVL gene and remained similar
when adjusted for covariates (data not
shown). Whereas those with PVL(–) versus
PVL(1) strains had a similar proportion
of P. aeruginosa–positive cultures, those
acquiring PVL(1) isolates had more
cultures taken in the 2 years before MRSA
detection; the mean (SD) cultures/
participant/24 months for those with
PVL(–) versus PVL(1) strains was 4.2 (2.9)
versus 6.2 (4.5), respectively (P = 0.02). The
number of cultures increased after MRSA
detection in those with either PVL(–) and
PVL(1) strains; the mean (SD) cultures/
participant/24 months for those with
PVL(–) versus PVL(1) strains was 8.9 (3.8)
versus 9.2 (3.8), respectively (P = 0.67).
Discussion
In this multicenter study, initial detection of
MRSA in children and adolescents with CF
occurred at 7 years of age and was similar
among those with different SCCmec types;
20% of participants were less than 3 years
of age at the time of their first MRSA-
positive culture. The proportion of SCCmec
IV strains, both PVL(–) and PVL(1),
increased from 1996 to 2010. The increase
in SCCmec IV types during this time
interval is consistent with the increase in
community-associated (SCCmec IV) MRSA
infections in the general U.S. population
(8, 33). Our prior study in this CF study
population has shown that the SCCmec IV
isolates are usually USA300 (19). Further,
despite some geographic variation of MRSA
prevalence within the United States among
non-CF patients (34), we found that the
distribution of SCCmec II versus SCCmec
IV strains did not differ by region (19).
We explored the association of various
SCCmec types with CF health status within
the 2 years before detection of MRSA and
with health care exposures and antibiotic
use within the 6 months before detection.
These two time intervals were selected to
assess various risk factors for MRSA (13,
35, 36); underlying health status often
shows slower changes over time in contrast
to the short-term health care exposures that
could result in acquisition of HA-MRSA,
that is, SCCmec II strains. Furthermore,
both exposure and outcome can be
measured in this shorter interval as patients
with CF are seen at regular intervals and
need to produce respiratory cultures
frequently. Although CF health status was
not associated with acquisition of a specific
MRSA type, P. aeruginosa–positive cultures
and an increased number of CF clinic
visits were associated with SCCmec II.
Acquisition of P. aeruginosa has been
associated with more clinic visits in newborn
screening studies (37, 38), and P. aeruginosa
is transmissible from CF patient to CF
patient (39). At present, it remains unclear
whether CF clinic visits and/or P. aeruginosa
are risks for acquiring SCCmec II MRSA.
Outcomes after MRSA acquisition
showed a general intensification of care
among all participants as evidenced by an
increased number of clinic visits and use of
CF medications. Of note, SCCmec type and
PVL status were not known to the treating
physicians in this study, and thus MRSA
type did not influence treatment decisions.
However, the use of inhaled antibiotics and
more IV antibiotic days increased only in
participants with SCCmec II strains within
6 months of MRSA acquisition. Both of
Table 4. Changes in clinical parameters 2 years before, compared with after, detection of various methicillin-resistant
Staphylococcus aureus types
Change within SCCmec II
(n = 205)
Change within SCCmec IV
(n = 90)
Adjusted* Difference between SCCmec Type
(SCCmec II–SCCmec IV)
n Mean 95% CI n Mean 95% CI Mean Difference 95% CI P Value
Health status
FEV1% predicted 110 22.40 –3.99, –0.72 43 22.64 –5.29, –0.01 20.17 –4.50, 4.17 0.94
BMI or weight/stature
percentile
196 0.22 –2.00, 2.43 80 1.32 –2.19, 4.83 20.022 –5.74, 5.69 0.99
CF medications 205 90
Chronic inhaled antibiotics 32.20% 24.56, 39.83 14.44% 2.88, 26.01 12.31% –7.10, 31.72 0.21
Chronic DNase 27.32% 21.02, 33.62 25.56% 15.85, 35.26 11.16% –3.62, 25.94 0.14
Chronic macrolides 24.88% 18.76, 31.00 21.11% 12.52, 29.71 14.27% –1.51, 30.07 0.076
Days of IV antibiotics per
IV course†‡
160 1.66 0.09, 3.23 81 2.45 –0.57, 5.47 20.60 –4.53, 3.33 0.76
Microbiology 205 90
Any P. aeruginosa 1.00% –7.09, 9.04 17.78% 6.64, 28.91 212.25% –27.76, 3.25 0.12
Health care exposure
CF clinic visits 205 4.23 3.38, 5.08 90 5.44 3.56, 7.31 20.49 –3.07, 2.10 0.71
>1 Hospitalization 205 12.7% 4.8, 20.6 90 7.8% –5.5, 20.0 3.2% –11.7, 18.0 0.67
Days inpatient per
hospitalization
160 0.92 –0.23, 2.08 81 2.19 –0.47, 4.85 21.82 –4.90, 1.26 0.25
Definition of abbreviations: BMI = body mass index; CF = cystic fibrosis; CI = confidence interval; IV = intravenous; MRSA =methicillin-resistant
Staphylococcus aureus; P. aeruginosa = Pseudomonas aeruginosa; SCCmec = staphylococcal cassette chromosome mec.
Changes are shown for characteristics 2 years before compared with 2 years after MRSA per SCCmec type. Boldface represents significance at the
two-sided 0.05 level.
*Comparisons by SCCmec type are adjusted for site, sex, age, year of MRSA onset, and P. aeruginosa during the 24 months after MRSA acquisition.
†Evaluable in n = 160 SCCmec II and n = 81 SCCmec IV with data after 2003.
‡Combined inpatient and outpatient intravenous therapy.
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these observations may reflect the higher
prevalence of P. aeruginosa in this group,
and the latter could be explained by the
higher rate of antibiotic resistance genes in
SCCmec II isolates requiring IV antibiotics.
Overall, similar trends in care intensification
were noted when the observation time was
extended to 2 years. We can only speculate
whether intensification of care reflects
a response to progression of CF lung disease
as evidenced in the decline in lung function
observed in both groups, or is related to
patient and clinician concerns after detection
of MRSA. Others have reported initiation of
CF therapies not directly targeting MRSA,
use of inhaled tobramycin, was higher in
subjects with MRSA compared with MSSA
despite similar prevalence of P. aeruginosa
(40, 41).
Our findings that participants with
PVL(–) isolates had more hospital
admissions within the 6 months after
MRSA detection than those with PVL(1)
isolates are somewhat at odds with prior
reports of acute necrotizing pneumonia in
children with CF (17) or previously healthy
people (15, 16).
In the current analyses we lack
information on the use of oral antibiotics
targeting MRSA as these data have been
available in the CF Patient Registry only
since 2012. However, we previously
demonstrated that those participants with
longstanding SCCmec II MRSA infection
had more exacerbations and increased use
of oral antibiotics compared with those
with SCCmec IV MRSA (25). We suggest
that differences in study design may explain
the seemingly different results in the
current study compared with our prior
study that prospectively evaluated
exacerbations in the same participants.
These differences include the duration of
MRSA infections, that is, 3–4 years in the
prior study versus the maximum 2 years
in the current study and the outcome
measures assessed, that is, symptoms and
use of oral antibiotics versus the variables
available in the CF Patient Registry. Future
multicenter, prospective studies would be
necessary to further evaluate the association
of MRSA-specific factors, underlying
disease severity, and clinical care practices
with patient outcomes.
Although we cannot prove causality in
this epidemiologic study, the higher rate of
clinic visits and P. aeruginosa, which is also
transmissible, could imply a health care–
related source of infection for those with
SCCmec II and thus argue for strict infection
control policies. Combined with our prior
observation of more exacerbations in
subjects with chronic SCCmec II MRSA
compared with those with SCCmec IV,
knowledge of SCCmec status may be
beneficial both regarding epidemiologic/risk
assessment and subsequent treatment
decisions. Again, firm conclusions should
be made cautiously, based solely on
epidemiologic studies; however, the higher
use of antibiotics seen in our prior study and
other risks may indicate that MRSA-specific
therapies should be intensified in patients
acquiring SCCmec II isolates.
There are limitations to this study.
Although this is a multicenter study, it
is unknown whether our findings are
generalizable to all patients with CF,
including adults, or to those with transient
MRSA. Lung function is not reliably tested
in children less than 6 years of age, but the
proportion of participants without lung
function data was similar across MRSA
types. Hospitalizations and intravenous
antibiotic treatment were not recorded
before 2003. These missing data affect
power, but are unlikely to cause bias.
Although the ability to use data in the
Registry since 1996 can enhance participant
inclusion and follow-up, it is likely that
changes in medical management that
occurred over time can influence outcomes.
Finally, being an exploratory study,
adjustment for multiple testing was not
performed, and therefore spurious findings
cannot be ruled out.
In conclusion, we demonstrate that
first detection of MRSA occurred in early
childhood among those who go on to
have persistent infection. Presence of any
P. aeruginosa–positive culture and an
increased number of CF clinic visits
6 months before initial MRSA detection
adjusted for P. aeruginosa status were
potential risk factors associated with
acquisition of SCCmec II MRSA implicating
patient and care-related risks. There was no
increased morbidity in those with PVL(1)
isolates. Short-term changes after initial
MRSA detection showed increases in
multiple chronic medications and clinic visits
for all participants and, when adjusting for
covariates, was similar among the various
SCCmec types. To better delineate changes
that occur during transition from early to
chronic MRSA infection, translational and
ideally prospective studies that study bacterial
changes and host factors will be necessary. n
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